孕36周母体血清糖基化纤连蛋白与血管生成标志物筛查子痫前期
本研究为病例对照研究,纳入100例子痫前期、100例妊娠期高血压和600例对照,评估孕35+0至36+6周血清糖基化纤连蛋白(GlyFn)联合母体因素、平均动脉压(MAP)、子宫动脉搏动指数(UtA-PI)、胎盘生长因子(PlGF)和可溶性fms样酪氨酸激酶-1(sFlt-1)对足月子痫前期和妊娠期高血压的预测性能,并与孕11+0至13+6周筛查比较。结论认为GlyFn是晚孕期筛查的潜在有用标志物,但病例对照研究结果需前瞻性筛查研究验证。
要点
- 孕35+0至36+6周三联试验(母体因素+MAP+PlGF+sFlt-1)对筛查后3周内子痫前期检出率为83.7%(95%CI 70.3-92.7%)。
- 加用GlyFn未提高三联试验的筛查性能。
- 孕35+0至36+6周筛查对足月子痫前期和妊娠期高血压的预测性能远优于孕11+0至13+6周筛查。
核心结论
- GlyFn是晚孕期筛查足月子痫前期和足月妊娠期高血压的潜在有用生物标志物,但该病例对照研究结果需前瞻性筛查研究验证。
研究设计与样本
- 病例对照研究,从非干预筛查研究中选取孕35+0至36+6周单胎妊娠孕妇的储存样本,使用即时检测设备测定母体血清GlyFn。
- 纳入孕37周及以上分娩者,包括100例发生子痫前期、100例发生妊娠期高血压和600例未发生子痫前期或妊娠期高血压的对照。
- 所有对象在孕35+0至36+6周常规就诊时测量MAP、UtA-PI、PlGF和sFlt-1,部分对象有孕11+0至13+6周检查样本。
主要发现
- 在10%固定假阳性率下,三联试验(母体危险因素+MAP+PlGF+sFlt-1)对筛查后3周内子痫前期分娩的检出率为83.7%(95%CI 70.3-92.7%),对筛查后任何时间子痫前期分娩的检出率为80.0%(95%CI 70.8-87.3%),加用GlyFn未改善该性能。
- 母体危险因素+MAP+PlGF+GlyFn组合的筛查性能与三联试验相似,无论对筛查后3周内还是任何时间的子痫前期分娩。
- 母体危险因素+MAP+UtA-PI+GlyFn组合的筛查性能与三联试验相似,两者均优于单纯低PlGF浓度筛查(3周内子痫前期检出率65.3%(95%CI 50.4-78.3%),任何时间56.0%(95%CI 45.7-65.9%))或高sFlt-1/PlGF浓度比筛查(3周内73.5%(95%CI 58.9-85.1%),任何时间63.0%(95%CI 52.8-72.4%))。
- 孕35+0至36+6周筛查对孕37周及以上子痫前期和妊娠期高血压分娩的预测性能远优于孕11+0至13+6周筛查。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该研究为病例对照研究,原文结论指出其发现需前瞻性筛查研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: First, to examine the predictive performance of maternal serum glycosylated fibronectin (GlyFn) at 35 + 0 to 36 + 6 weeks' gestation in screening for delivery with pre-eclampsia (PE) and delivery with gestational hypertension (GH) at ≥ 37 weeks' gestation, both within 3 weeks and at any time after the examination. Second, to compare the predictive performance for delivery with PE and delivery with GH of various combinations of biomarkers, including GlyFn, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). Third, to compare the predictive performance for delivery with PE and delivery with GH by serum PlGF concentration, sFlt-1/PlGF concentration ratio and the competing-risks model with different combinations of biomarkers as above. Fourth, to compare the predictive performance of screening at 11 + 0 to 13 + 6 weeks vs 35 + 0 to 36 + 6 weeks for delivery with PE and delivery with GH at ≥ 37 weeks' gestation. METHODS: This was a case-control study in which maternal serum GlyFn was measured in stored samples from a non-intervention screening study in singleton pregnancies at 35 + 0 to 36 + 6 weeks' gestation using a point-of-care device. We used samples from women who delivered at ≥ 37 weeks' gestation, including 100 who developed PE, 100 who developed GH and 600 controls who did not develop PE or GH. In all cases, MAP, UtA-PI, PlGF and sFlt-1 were measured during the routine visit at 35 + 0 to 36 + 6 weeks. We used samples from patients that had been examined previously at 11 + 0 to 13 + 6 weeks' gestation. Levels of GlyFn were transformed to multiples of the expected median (MoM) values after adjusting for maternal demographic characteristics and elements from the medical history. Similarly, the measured values of MAP, UtA-PI, PlGF and sFlt-1 were converted to MoM. The competing-risks model was used to combine the prior distribution of the gestational age at delivery with PE, obtained from maternal risk factors, with various combinations of biomarker MoM values to derive the patient-specific risks of delivery with PE. The performance of screening of different strategies was estimated by examining the detection rate (DR) at a 10% fixed false-positive rate (FPR) and McNemar's test was used to compare the DRs between the different methods of screening. RESULTS: The DR, at 10% FPR, of screening by the triple test (maternal risk factors plus MAP, PlGF and sFlt-1) was 83.7% (95% CI, 70.3-92.7%) for delivery with PE within 3 weeks of screening and 80.0% (95% CI, 70.8-87.3%) for delivery with PE at any time after screening, and this performance was not improved by the addition of GlyFn. The performance of screening by a combination of maternal risk factors, MAP, PlGF and GlyFn was similar to that of the triple test, both for delivery with PE within 3 weeks and at any time after screening. The performance of screening by a combination of maternal risk factors, MAP, UtA-PI and GlyFn was similar to that of the triple test, and they were both superior to screening by low PlGF concentration (PE within 3 weeks: DR, 65.3% (95% CI, 50.4-78.3%); PE at any time: DR, 56.0% (95% CI, 45.7-65.9%)) or high sFlt-1/PlGF concentration ratio (PE within 3 weeks: DR, 73.5% (95% CI, 58.9-85.1%); PE at any time: DR, 63.0% (95% CI, 52.8-72.4%)). The predictive performance of screening at 35 + 0 to 36 + 6 weeks' gestation for delivery with PE and delivery with GH at ≥ 37 weeks' gestation was by far superior to screening at 11 + 0 to 13 + 6 weeks. CONCLUSION: GlyFn is a potentially useful biomarker in third-trimester screening for term PE and term GH, but the findings of this case-control study need to be validated by prospective screening studies. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Sokratous N, Wright A, Syngelaki A, et al. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation. Ultrasound Obstet Gynecol. 2024. PMID: 37724582. doi:10.1002/uog.27481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。